DBV Technologies S.A. Total Liabilities
DBV Technologies S.A. total liabilities. Based on the latest financial reports, DBV Technologies S.A. (DBV) has total liabilities worth €58.50 Million EUR (≈ $68.39 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See DBV Technologies S.A. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of DBV Technologies S.A. (2007–2025)
Total liabilities of DBV Technologies S.A. from 2007 to 2025. This chart illustrates how DBV Technologies S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of DBV Technologies S.A. to evaluate the company's liquid asset resilience ratio.
DBV Technologies S.A. Competitors by Total Liabilities
The table below lists competitors of DBV Technologies S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cromwell Property Group
AU:CMW
|
Australia | AU$887.80 Million |
|
PPC Ltd
JSE:PPC
|
South Africa | ZAC4.03 Billion |
|
TTY Biopharm Co Ltd
TWO:4105
|
Taiwan | NT$4.28 Billion |
|
Suzhou Etron Technologies Co Ltd
SHG:603380
|
China | CN¥1.06 Billion |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
China | CN¥5.65 Billion |
|
CHINA VANKE CO.LTD H YC 1
F:18V
|
Germany | €769.34 Billion |
|
Vats Liquor Chain Store Management Joint Stock Co Ltd
SHE:300755
|
China | CN¥2.07 Billion |
|
Relx PLC
LSE:REL
|
UK | GBX12.37 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down DBV Technologies S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DBV Technologies S.A. total assets.
Liquidity & Leverage Metrics
DBV Technologies S.A. Total Liabilities Ratios Explained
DBV Technologies S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DBV Technologies S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DBV Technologies S.A. (2007–2025)
The table below shows the annual total liabilities of DBV Technologies S.A. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €64.96 Million ≈ $75.94 Million |
+69.73% |
| 2024-12-31 | €38.27 Million ≈ $44.74 Million |
-10.58% |
| 2023-12-31 | €42.80 Million ≈ $50.04 Million |
-17.69% |
| 2022-12-31 | €52.00 Million ≈ $60.79 Million |
+9.59% |
| 2021-12-31 | €47.45 Million ≈ $55.47 Million |
-42.04% |
| 2020-12-31 | €81.87 Million ≈ $95.71 Million |
-7.87% |
| 2019-12-31 | €88.86 Million ≈ $103.88 Million |
+28.82% |
| 2018-12-31 | €68.98 Million ≈ $80.64 Million |
+2.33% |
| 2017-12-31 | €67.40 Million ≈ $78.80 Million |
+36.84% |
| 2016-12-31 | €49.26 Million ≈ $57.59 Million |
+94.72% |
| 2015-12-31 | €25.30 Million ≈ $29.57 Million |
+60.73% |
| 2014-12-31 | €15.74 Million ≈ $18.40 Million |
+46.90% |
| 2013-12-31 | €10.71 Million ≈ $12.52 Million |
+65.15% |
| 2012-12-31 | €6.49 Million ≈ $7.58 Million |
-4.40% |
| 2011-12-31 | €6.79 Million ≈ $7.93 Million |
+125.65% |
| 2010-12-31 | €3.01 Million ≈ $3.52 Million |
+36.99% |
| 2009-12-31 | €2.19 Million ≈ $2.57 Million |
+4.13% |
| 2008-12-31 | €2.11 Million ≈ $2.46 Million |
-4.27% |
| 2007-12-31 | €2.20 Million ≈ $2.57 Million |
-- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more